Biotechnology company Helaina has raised USD 45 million in Series B funding led by Avidity Partners, with participation from Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity, and Primary Venture Partners, among others. The funding brings Helaina's total equity funding to USD 83 million.
The new funding will be used to scale the availability of effera Human Lactoferrin, a novel ingredient that supports women's health, active nutrition, and healthy aging. Helaina plans to sell effera to consumer brands and through strategic distribution partners.
Helaina's effera is claimed to be the first and only human equivalent bioactive protein for nutrition to be used in functional foods, beverages, and supplements. The company has plans to make it available in several consumer products, including those from Kroma Wellness, The Feed, Levelle Nutrition, Healthgevity, and through distributor Mitsubishi International Food Ingredients, Inc.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.